Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06376045 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06376045 · ClinicalTrials.gov record · last posted 2026-08-11

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Name: A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma — clinical trial record (NCT06376045)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusTerminated

PhasePhase 2

SponsorAmgen

Started2024-05-24

View on ClinicalTrials.gov ↗

Why the trial stopped

Sponsor Decision

from the ClinicalTrials.gov record

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Protocol amendment history 3 changes detected by DataLookout

2026-08-12

Trial status changed: Completed → Terminated

2026-08-12

Trial terminated: Sponsor Decision

2026-07-03

Trial completed

Trial Details

NCT Number	NCT06376045
Lead Sponsor	Amgen
Conditions	Asthma
Enrollment	317 participants
Start Date	2024-05-24
Primary Completion	2026-05-14 (estimated)
Study Completion	2026-06-23 (estimated)
Updated on ClinicalTrials.gov	2026-08-11